how glp-1 agonists work Why are being used to treat patients with nonalcoholic fatty liver disease? Why are GLP-1 agonists being
Description
Henney 2024) demonstrated a potentially meaningful reduction in incident pneumonia with GLP-1 RAs compared with dipeptidyl peptidase-4 (DPP-4) inhibitors (hazard ratio [HR] 0.60, 95% confidence interval [CI] 0.580.62
Discover how GLP-1 receptor agonists like semaglutide may reduce inflammation beyond blood sugar control
For patients, oral therapies promise greater convenience, improved adherence, and broader access, particularly for those reluctant to use injectables
Weight Support*
The most common designs are observational studies
A smarter approach to appetite and metabolism
